Katherine Fuh MD PhD

PubMed

• 1 citations
  DDR2 Confers Ferroptosis Resistance to Cancer-Associated Fibroblasts and Attenuates PARPi Sensitivity of Ovarian Tumor Cells.
  Julien Lesage, Alessandra DiMauro, Angela M Schab, Seth Stidham, Mary M Mullen
  Molecular Cancer Research. 2025-12-02
• AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer.
  Jo'an Tankou, Sofia Ruau, Anjali Walia, Michael Toboni, Hollie Noia
  Gynecologic Oncology. 2025-11-20
• 1 citations
  In vivo genome-wide CRISPR screens in human T cells to enhance T cell therapy for solid tumors.
  Qi Liu, Peixin Amy Chen, Esha Urs, Shimin Zhang, Maya M Arce
  Biorxiv. 2025-09-24

Journal Articles

• Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer  
  Ian S Hagemann, Premal H Thaker, Carolyn K McCourt, Katherine C Fuh, David G Mutch, Andrea R Hagemann, Matthew A Powell, Clinical Cancer Research
• Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer  
  Ian S Hagemann, Carolyn K McCourt, Matthew A Powell, Premal H Thaker, David G Mutch, Katherine C Fuh, Andrea R Hagemann, Clinical Cancer Research

Lectures

• Identifying a potential biomarker for anti-PD-1 immunotherapy in patients with advanced stage, surgically-resectable endometrial cancer. 
  2019 ASCO Annual Meeting - 6/1/2019